{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:46:30Z","timestamp":1791283590953,"version":"4.1.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>About half of metastatic colorectal cancers (CRCs) harbor Rat Sarcoma (RAS) activating mutations as oncogenic driver, but the prognostic role of RAS mutations is not fully elucidated. Interestingly, specific hotspot mutations have been identified as potential candidates for novel targeted therapies in several malignancies as per G12C. This study aims at evaluating the association between KRAS hotspot mutations and patient characteristics, prognosis and response to antiangiogenic drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from RAS-mutated CRC patients referred to Careggi University Hospital, between January 2017 and April 2022 were retrospectively and prospectively collected. Tumor samples were assessed for RAS mutation status using MALDI-TOF Mass Spectrometry, Myriapod NGS-56G Onco Panel, or Myriapod NGS Cancer Panel DNA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 1047 patients with available RAS mutational status, 183 KRAS-mutated patients with advanced CRC had adequate data for clinicopathological and survival analysis. KRAS mutations occurred at codon 12 in 67.2% of cases, codon 13 in 23.5%, codon 61 in 2.2%, and other codons in 8.2%. G12C mutation was identified in 7.1% of patients and exon 4 mutations in 7.1%. KRAS G12D mutation, as compared to other mutations, was significantly associated with liver metastases (1-sided p=0.005) and male sex (1-sided p=0.039), KRAS G12C mutation with peritoneal metastases (1-sided p=0.035), KRAS G12V mutation with female sex (1-sided p=0.025) and no surgery for primary tumor (1-sided p=0.005). No associations were observed between specific KRAS variants and age, ECOG PS, site of primary tumor, pattern of recurrence for resected patients, and lung, distant lymph node, bone, or brain metastases.<\/jats:p><jats:p>Overall survival (OS) was significantly longer in patients with KRAS exon 4 mutations than in those with other KRAS mutations (mOS 43.6 months vs 20.6 months; HR 0.45 [0.21-0.99], p=0.04). No difference in survival was observed for mutations at codon 12\/13\/61 (p=0.1). Treatment with bevacizumab (BV) increased significatively mPFS (p=0.036) and mOS (p=0.019) of the entire population with a substantial benefit in mOS for G12V mutation (p=0.031).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patterns of presentation and prognosis among patients with specific RAS hotspot mutations deserve to be extensively studied in large datasets, with a specific attention to the uncommon isoforms and the role of anti-angiogenic drugs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.1055019","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T08:48:48Z","timestamp":1669711728000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"Daniele","family":"Lavacchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Fancelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Caliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Brugia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Vannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Bartoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Cianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Pillozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5114\/pg.2018.81072","article-title":"Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors","volume":"14","author":"Rawla","year":"2019","journal-title":"Prz Gastroenterol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis","volume":"11","author":"De Roock","year":"2010","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20854","article-title":"Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer","volume":"50","author":"Vaughn","year":"2011","journal-title":"Genes Chromosomes Cancer."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1038\/s41467-019-11530-0","article-title":"Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients","volume":"10","author":"Serebriiskii","year":"2019","journal-title":"Nat Commun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/PDM.0b013e3181c93fd1","article-title":"NRAS mutations are rare in colorectal cancer","volume":"19","author":"Irahara","year":"2010","journal-title":"Diagn Mol Pathol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14744\/ejmo.2017.22931","article-title":"Frequency of ras mutations (Kras, nras, hras) in human solid cancer","volume":"1","author":"Kodaz","year":"2017","journal-title":"EJMO"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605177","article-title":"KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer","volume":"101","author":"Loupakis","year":"2009","journal-title":"Br J Cancer."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0804385","article-title":"K-Ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/annonc\/mdu378","article-title":"Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials","volume":"26","author":"Sorich","year":"2015","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3210","article-title":"Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers","volume":"18","author":"Imamura","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.37","article-title":"Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer","volume":"116","author":"Jones","year":"2017","journal-title":"Br J Cancer."},{"key":"B13","article-title":"Relationship of ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study","volume":"9","author":"Samowitz","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1964","article-title":"Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study","volume":"85","author":"Andreyev","year":"2001","journal-title":"Br J Cancer."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00605-7","article-title":"Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial","volume":"23","author":"Fakih","year":"2022","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1158\/1538-7445.AM2021-1260","article-title":"First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant cancers [abstract]","volume":"81","author":"Koltun","year":"2021","journal-title":"Proc Am Assoc Cancer Res Annu Meeting 2021"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged","volume":"19","author":"Moore","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"1). Eur J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100040","article-title":"Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of molecular tumor boards","volume":"6","author":"Danesi","year":"2021","journal-title":"ESMO Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"100740","DOI":"10.1016\/j.tranon.2020.01.001","article-title":"hERG1 and HIF-2\u03b1 behave as biomarkers of positive response to bevacizumab in metastatic colorectal cancer patients","volume":"13","author":"Iorio","year":"2020","journal-title":"Transl Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.413","article-title":"Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer","volume":"116","author":"Marmorino","year":"2017","journal-title":"Br J Cancer."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2016.08.006","article-title":"Efficacy and safety of bevacizumab combined with fluoropyrimidine monotherapy for unfit or older patients with metastatic colorectal cancer: A systematic review and meta-analysis","volume":"16","author":"Pinto","year":"2017","journal-title":"Clin Colorectal Cancer."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153863","article-title":"Aflibercept plus FOLFIRI as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience","volume":"13","author":"Lavacchi","year":"2021","journal-title":"Cancers (Basel)."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2747","article-title":"Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis","volume":"9","author":"Bylsma","year":"2020","journal-title":"Cancer Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13870","article-title":"The prognostic impact of KRAS G12C mutation in patients with metastatic colorectal cancer: A multicenter retrospective observational study","volume":"26","author":"Chida","year":"2021","journal-title":"Oncologist"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2020.04.009","article-title":"KRAS G12C metastatic colorectal cancer: Specific features of a new emerging target population","volume":"19","author":"Schirripa","year":"2020","journal-title":"Clin Colorectal Cancer."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.826073","article-title":"KRAS-G12C mutation in one real-life and three population-based Nordic cohorts of metastatic colorectal cancer","volume":"12","author":"Osterlund","year":"2022","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100567.","article-title":"Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)","volume":"7","author":"Ciardiello","year":"2022","journal-title":"ESMO Open"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8010111","article-title":"Colorectal cancer prognosis is not associated with BRAF and KRAS mutations-a STROBE compliant study","volume":"8","author":"Lee","year":"2019","journal-title":"J Clin Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1570","article-title":"KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803","volume":"15","author":"Ogino","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"14609","DOI":"10.1038\/s41598-021-94044-4","article-title":"Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX","volume":"11","author":"Park","year":"2021","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab190","article-title":"KRAS and BRAF mutations in stage II and III colon cancer: A systematic review and meta-analysis","volume":"114","author":"Formica","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01254","article-title":"Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy","volume":"37","author":"Morano","year":"2019","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx089","article-title":"ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer","volume":"109","author":"Pietrantonio","year":"2017","journal-title":"J Nat Can Inst"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.11.018","article-title":"Tumour mutational burden predicts resistance to EGFR\/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer","volume":"161","author":"Randon","year":"2022","journal-title":"Eur J Cancer."},{"key":"B36","doi-asserted-by":"publisher","first-page":"PO.21.00223","DOI":"10.1200\/PO.21.00223","article-title":"KRAS A146 mutations are associated with distinct clinical behavior in patients with colorectal liver metastases","volume":"5","author":"van 't Erve","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2017.08.006","article-title":"KRAS alleles: The devil is in the detail","volume":"3","author":"Haigis","year":"2017","journal-title":"Trends Cancer."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1220","article-title":"Tissue-specific oncogenic activity of KRASA146T","volume":"9","author":"Poulin","year":"2019","journal-title":"Cancer Discovery"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01088","article-title":"A comparative analysis of individual RAS mutations in cancer biology","volume":"9","author":"Mu\u00f1oz-Maldonado","year":"2019","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0192","article-title":"Genomic and biological characterization of exon 4 KRAS mutations in human cancer","volume":"70","author":"Janakiraman","year":"2010","journal-title":"Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.7150\/jca.59193","article-title":"Prognostic value of KRAS exon 3 and exon 4 mutations in colorectal cancer patients","volume":"12","author":"Guo","year":"2021","journal-title":"J Cancer."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-135","article-title":"Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review","volume":"13","author":"Imamura","year":"2014","journal-title":"Mol Cancer."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0142","article-title":"BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition","volume":"11","author":"Hofmann","year":"2021","journal-title":"Cancer Discovery"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0650-4","article-title":"KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials","volume":"30","author":"Petrelli","year":"2013","journal-title":"Med Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-4523-7","article-title":"G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab","volume":"37","author":"Fiala","year":"2016","journal-title":"Tumour Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/s1535-6108(03)00030-8","article-title":"Ras modulates myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis","volume":"3","author":"Watnick","year":"2003","journal-title":"Cancer Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/22788","article-title":"Essential role for oncogenic ras in tumour maintenance","volume":"400","author":"Chin","year":"1999","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","first-page":"A110","DOI":"10.1161\/str.53.suppl_1.110","article-title":"Abstract 110: Inhibition of VEGF signaling prevents KRASG12V-induced brain arteriovenous malformations","volume":"53","author":"Park","year":"2022","journal-title":"Stroke"},{"key":"B49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3892\/ol.2020.12276","article-title":"KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation","volume":"21","author":"Lastraioli","year":"2021","journal-title":"Oncol Lett"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i15.1503","article-title":"Liquid biopsy in colorectal cancer: No longer young, but not yet old","volume":"28","author":"Roviello","year":"2022","journal-title":"World J Gastroenterol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000923","article-title":"Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report","volume":"31","author":"Lastraioli","year":"2020","journal-title":"Anticancer Drugs"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14041052","article-title":"Dynamics of RAS\/BRAF mutations in cfDNA from metastatic colorectal carcinoma patients treated with polychemotherapy and anti-EGFR monoclonal antibodies","volume":"14","author":"Rachiglio","year":"2022","journal-title":"Cancers (Basel)."},{"key":"B53","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41416-021-01399-6","article-title":"Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study","volume":"125","author":"Salvianti","year":"2021","journal-title":"Br J Cancer."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1055019\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T08:48:51Z","timestamp":1669711731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1055019\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":53,"alternative-id":["10.3389\/fonc.2022.1055019"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1055019","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"article-number":"1055019"}}